Related Experiment Video

Updated: May 12, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Mitosis-targeting therapies: a troubleshooting guide

Elena Doménech1, Marcos Malumbres

  • 1Cell Division and Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Current Opinion in Pharmacology
|April 16, 2013
PubMed

Insights

Targeting mitotic kinases and kinesins shows promise for cancer treatment, but current methods lack selectivity and cause side effects. Future research needs more specific inhibitors and targeted strategies for better tumor cell targeting.

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Mitotic kinases and kinesins are crucial for cell division and often overexpressed in human tumors, making them potential cancer targets.
  • Current limitations include poor selectivity for tumor cells, low mitotic cell percentages in tumors, and dose-limiting side effects, leading to restricted clinical responses.

Purpose of the Study:

  • To evaluate the potential of targeting mitotic processes in cancer therapy.
  • To identify strategies for overcoming the limitations of current anti-mitotic agents.

Main Methods:

  • Review of existing literature on mitotic kinases and kinesins as cancer targets.
  • Analysis of challenges in clinical applications of anti-mitotic therapies.
  • Exploration of future research directions for improved cancer treatment strategies.

Main Results:

  • Mitotic kinases and kinesins play a vital role in cell division and are implicated in various human cancers.
  • Clinical trials of existing mitotic inhibitors have yielded limited success due to selectivity and side effect issues.
  • Further development requires enhanced inhibitor specificity, better pharmacodynamic profiles, and a deeper understanding of target cell requirements.

Conclusions:

  • Inhibiting mitosis remains a promising cancer therapy strategy despite current challenges.
  • Future advancements necessitate the development of highly specific inhibitors and rational therapeutic strategies, such as synthetic lethality, to improve tumor cell selectivity and treatment efficacy.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel08:29

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...